Skip to main content

Table 3 TNF-α and IL-10 production in LPS challenged PBMCs incubated with oligosaccharide fractions

From: In vitro evaluation of defined oligosaccharide fractions in an equine model of inflammation

  TNF- α (pg/ml)    IL-10 (pg/ml)   
Incubation Point estimate Lower bound Upper bound Point estimate Lower bound Upper bound
LPS 1 μg/ml 1749.4 1495.2 2050.8 278.1 236.0 328.7
LPS + GOS 0.5% 3655.5 * 3115.0 4285.5 293.8 248.4 347.6
LPS + GOS 1.0% 4989.0 * # 4251.4 5843.0 268.8 227.5 316.7
LPS + GOS 2.0% 7754.3 * # 6607.8 9090.6 265.6 225.0 313.6
LPS + GOS/FOS 0.5% 3601.1 * 3074.8 4221.7 344.1 290.9 407.5
LPS + GOS/FOS 1.0% 5530.3 * # 4712.6 6483.4 307.4 260.6 362.9
LPS + GOS/FOS 2.0% 6721.1 * 5733.0 7879.3 264.0 223.9 311.7
LPS + GOS/FOS/AOS 0.5% 4242.9 * 3608.3 4969.1 374.3 * 317.0 442.3
LPS + GOS/FOS/AOS 1.0% 3317.6 * # 2832.7 3893.3 269.6 # 227.9 318.3
LPS + GOS/FOS/AOS 2.0% 1029.7 * # 874.8 1205.9 180.7 * # 149.0 216.6
  1. Mean protein concentrations of TNF-α and IL-10 (pg/ml) and 95% Bayesian Credible Intervals for LPS challenged PBMCs incubated with oligosaccharide fractions (including incubations with LPS alone). Significant differences between oligosaccharide fractions and LPS alone are marked with an asterisk (*). Significant dose-dependent differences (1.0% vs. 0.5% and 2.0% vs. 1.0%) are marked with a hash (#).